| 8:00 am - 5:00 pm |
Exhibition |
| 8:00 am - 9:00 am |
Continental Breakfast & Registration |
| 9:00 am - 9:05 am |
Welcome - Presiding
Feng Tian, Program Chair, Vice President, San Diego Chinese Association
|
| 9:05 am - 9:25 am |
Opening Remarks
Hui Cai, President, San Diego Chinese Association
Alan Paau, Assistant Vice Chancellor, UCSD
|
| 9:25 am - 11:40 am |
The Changing Landscape of Biopharmaceutical Industry
Ballroom B, with coffee break at 10:25 am |
|
Session Chairs: John Kozarich, President & Chairman, ActivX Biosciences, Inc.
Xiangdong Fu, Professor of Cellular and Molecular Medicine, UCSD
|
|
San Diego: Making an Eco-System for Innovation [Presentation: PDF]
Joseph D. Panetta, President and CEO, BIOCOM |
|
Biopharmaceutical Industry – “Something Old, Something New, Something Borrowed, Something Blue,” [abstract]
Henry Pan, Chief Medical Officer and Executive Vice President, Neurocrine Biosciences |
|
Role of Gut Hormones in the Treatment of Diabetes and Obesity [abstract]
Alain D. Baron, Senior Vice President of Research,
Amylin Pharmaceuticals, Inc.
|
|
The Developmental Role of Stem Cells May Suggest Novel Therapeutic Applications [abstract]
Evan Snyder, Professor and Director, The Burnham Institute.
|
| 11:40 am - 12:00 am |
Annual Symposium Award Presentation
Ballroom B |
|
To Be Announced
|
| 12:00 pm - 1:30 pm |
Luncheon
|
| 1:30 pm - 4:00 pm |
Drugs of the Future: From Bench to Bedside (Breakout Session 1)
Ballroom B |
|
Session Chair: Thomas R. Beattie, Biopharma Consultant
|
|
A New Inducible RNAi Model for Cancer Target Validation in vivo [abstract]
Henry Li, Director of Oncology, Immusol, Inc.
|
|
Optimization of Antibodies by Molecular Evolution
Gerhard Frey, Principal Scientist, Diversa Corporation.
|
|
Development of a Novel Phosphoinositide 3-kinase Inhibitor for the Reduction of Myocardial Infarction [abstract]
John Doukas, Senior Director, Cardiovascular Biology, TargeGen.
|
| AMG 476, a Potent and Selective Inhibitor of Mitogen-Activated Protein Kinase [abstract]
Dawei Zhang, Principal Scientist, Amgen
|
|
T Cell Therapy: Cancer and Beyond
Zeling Cai, Principal Scientist, Johnson & Johnson PRD La Jolla.
|
|
Novel Technology for in vivo expression and delivery of biopharmaceutical products
Wei Chen, Chief Operating Officer, Symbiotix Inc.
|
|
Clinical Trial, Regulation and Potentials [abstract]
Hua Jin, Assistant Clinical Professor, UCSD
|
| 1:30 pm - 4:00 pm |
Panel Discussion: R&D Business Strategies (Breakout Session 2)
Ballroom A |
|
Moderator
: Eddie Wang Rodriguez, Principal, Fish & Richardson, P.C. |
| Partnering with the University [abstract]
Jane Moores, Assistant Director, Technology Transfer and Intellectual Property Services, UCSD |
| Developing Successful Partnerships [abstract]
Beverly A. Cormier, President, BioScience Business Solutions
|
| Strategies for Reducing R&D Cycle Time [abstract]
Janet White, Senior Director of Business Operations for Development, Pfizer Global R&D, La Jolla
|
| How to Win the Outsourcing Game? -- WuXi PharmaTech’s Perspective.
[abstract]
Hai Mi, Senior Director of Strategic Planning, WuXi PharmaTech, Shanghai, China
|
| CapitalBio Corporation: A Successful Biotech Company in China [abstract]
Weiping Yang, Senior Vice President of Proteomics, CapitalBio Corporation, Beijing, China
|
| 4:00 pm - 5:00 pm |
Reception and Networking
|
| 5:00 pm |
Closing
|
| Final program as of May 28, 2005. All events will take place at the Price Center of UCSD.
|
.gif){kind=small}
